Form 4: Outlook Therapeutics Director Acquires Shares

Outlook Therapeutics Director Yezan Munther Haddadin reported the acquisition of 34,000 common shares on May 26, 2026.

Summary

• Yezan Munther Haddadin, a Director at Outlook Therapeutics, Inc., acquired 34,000 shares of common stock on May 26, 2026.
• The purchase price for these shares was $0.44 per share.
• Following this transaction, Haddadin beneficially owns 37,167 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's personal investment in the company, but it does not provide operational or financial performance updates.

Positives

• Director's investment in the company's stock, signaling confidence.
• Acquisition of 34,000 shares at a price of $0.44 per share.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, can provide insights into management's perception of the company's value and future prospects. The acquisition of shares by a director may be interpreted as a positive signal by the market.

Stakeholder Impact

• Shareholders may view the director's purchase as a sign of confidence in the company's future, potentially influencing investment decisions.

Key Dates

Keywords

Outlook Therapeutics, OTLK, Form 4, Insider Trading, Director Transaction, Common Stock, Securities Acquisition